This study is testing a new eye drop, GLK-221 Ophthalmic Solution, for people with keratoconus. Keratoconus is an eye condition where the clear front surface of the eye (cornea) thins and bulges outwards. You would receive either GLK-221 Ophthalmic Solution or a placebo (an inactive solution) twice a day in both eyes. Researchers want to see if GLK-221 Ophthalmic Solution is safe and if it can improve the shape of the cornea. To join, you must be between 18 and 55 years old and have a diagnosis of keratoconus. Pregnant or breastfeeding individuals, or those in another drug or device study, cannot participate. The study aims to enroll 100 participants, but its current status is unclear.

Study design

This is a multi-center, parallel-group, placebo-controlled study. This means some participants will receive the active drug and others a placebo, and neither you nor your doctor will know which you are receiving. The study plans to enroll 100 participants.

What's involved

You would administer the assigned eye drops twice daily to both eyes. The primary measurement for the study is taken at 16 weeks.

Compensation

Not stated in the trial record.

Follow-up

The main measurement for the study is taken at 16 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.